XNYS
A
Market cap47bUSD
Oct 08, Last price
168.17USD
1D
-0.54%
1Q
25.23%
Jan 2017
269.12%
Name
Agilent Technologies Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
Related entities
Subsidiaries (7)
AGILENT TECHNOLOGIES LUXCO LLC
AGILENT TECHNOLOGIES SALES (MALAYSIA) SDN. BHD.
AGILENT TECHNOLOGIES SINGAPORE (HOLDINGS) PTE. LTD.
AGILENT TECHNOLOGIES (CHINA) CO., LTD.
Agilent technologies Korea Ltd
AGILENT TECHNOLOGIES LDA MALAYSIA SDN. BHD.
AGILENT TECHNOLOGIES TRADING (SHANGHAI) CO., LTD.
Key people
Non-Executive Independent Chairman of the Board · since 2017
Adam Elinoff
Chief Financial Officer, Senior Vice President · since 2025
Senior Vice President, Chief Legal Officer, Secretary · since 2024
Jonah Kirkwood
Senior Vice President, Agilent and Chief Commercial Officer, Commercial Organization · since 2024
Simon May
Senior Vice President, President - Life Sciences and Diagnostics Markets Group · since 2024
Padraig McDonnell
Senior Vice President, President - Agilent CrossLab Group · since 2020
Angelica Riemann
Senior Vice President, Agilent President, Agilent CrossLab · since 2024
Mike Zhang
Senior Vice President, Agilent President, Applied Markets Group · since 2024
Investment Manager · since 2025
Rodney Gonsalves
Vice President, Corporate Controller, Principal Accounting Officer · since 2025
Padraig Mcdonnell
Chief Executive Officer, Director · since 2024
Mala Anand
Independent Director · since 2019
Independent Director · since 2021
Independent Director · since 2021
Daniel Podolsky
Independent Director · since 2015
Susan Rataj
Independent Director · since 2015
Independent Director · since 2014
Independent Director · since 2025
Independent Director · since 2018
Headquarters & legal address
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
WILMINGTON, DE 19801
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑10 | 2025‑04 | 2024‑10 | 2023‑10 | 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | 2018‑10 | 2017‑10 | 2016‑10 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||